EG24189A - 5-chloro-3-(-4-methanesulfonylphenyl)-6-methyl-[2,3] bipyridinyl in pure crystalline form and process for synthesis - Google Patents

5-chloro-3-(-4-methanesulfonylphenyl)-6-methyl-[2,3] bipyridinyl in pure crystalline form and process for synthesis

Info

Publication number
EG24189A
EG24189A EG20010540A EG20010540A EG24189A EG 24189 A EG24189 A EG 24189A EG 20010540 A EG20010540 A EG 20010540A EG 20010540 A EG20010540 A EG 20010540A EG 24189 A EG24189 A EG 24189A
Authority
EG
Egypt
Prior art keywords
methanesulfonylphenyl
bipyridinyl
chloro
synthesis
methyl
Prior art date
Application number
EG20010540A
Other languages
English (en)
Inventor
Crocker S Louis
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24189(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of EG24189A publication Critical patent/EG24189A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EG20010540A 2000-05-26 2001-05-22 5-chloro-3-(-4-methanesulfonylphenyl)-6-methyl-[2,3] bipyridinyl in pure crystalline form and process for synthesis EG24189A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20801700P 2000-05-26 2000-05-26

Publications (1)

Publication Number Publication Date
EG24189A true EG24189A (en) 2008-10-08

Family

ID=22772880

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010540A EG24189A (en) 2000-05-26 2001-05-22 5-chloro-3-(-4-methanesulfonylphenyl)-6-methyl-[2,3] bipyridinyl in pure crystalline form and process for synthesis

Country Status (48)

Country Link
EP (1) EP1296951B1 (enExample)
JP (2) JP3665053B2 (enExample)
KR (1) KR100757699B1 (enExample)
CN (1) CN1227233C (enExample)
AR (1) AR028577A1 (enExample)
AT (1) ATE483687T1 (enExample)
AU (2) AU6480401A (enExample)
BG (1) BG65855B1 (enExample)
BR (1) BRPI0111140B8 (enExample)
CA (1) CA2410234C (enExample)
CR (1) CR6606A (enExample)
CY (1) CY1111440T1 (enExample)
CZ (1) CZ20023888A3 (enExample)
DE (1) DE60143197D1 (enExample)
DK (1) DK1296951T3 (enExample)
EA (1) EA004809B1 (enExample)
EE (1) EE05242B1 (enExample)
EG (1) EG24189A (enExample)
ES (1) ES2351958T3 (enExample)
GC (1) GC0000362A (enExample)
GE (1) GEP20053492B (enExample)
GT (1) GT200100091A (enExample)
HN (1) HN2001000110A (enExample)
HR (1) HRP20020934B1 (enExample)
HU (1) HU228423B1 (enExample)
IL (1) IL152582A0 (enExample)
IN (2) IN2002CH02089A (enExample)
IS (1) IS2806B (enExample)
JO (1) JO2216B1 (enExample)
MA (1) MA26919A1 (enExample)
ME (1) ME00428B (enExample)
MX (1) MX230696B (enExample)
MY (1) MY123569A (enExample)
NO (1) NO324495B1 (enExample)
NZ (1) NZ522394A (enExample)
PA (1) PA8516901A1 (enExample)
PE (1) PE20011324A1 (enExample)
PH (1) PH12001001175B1 (enExample)
PL (1) PL358153A1 (enExample)
PT (1) PT1296951E (enExample)
RS (1) RS51541B (enExample)
SI (1) SI1296951T1 (enExample)
SK (1) SK287174B6 (enExample)
SV (1) SV2002000462A (enExample)
TW (1) TWI303634B (enExample)
UA (1) UA73355C2 (enExample)
WO (1) WO2001092230A1 (enExample)
ZA (1) ZA200209558B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
DK1248618T3 (da) 1999-11-29 2006-07-10 Merck Frosst Canada Inc Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
DK2479166T3 (da) 2009-02-27 2014-09-01 Cadila Healthcare Ltd Fremgangsmåde til fremstilling af etoricoxib
WO2012004677A1 (en) 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
WO2013105106A1 (en) 2011-11-03 2013-07-18 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
PL2887924T3 (pl) 2012-08-27 2017-09-29 Cadila Healthcare Limited Kompozycje farmaceutyczne etorykoksybu
WO2014041558A2 (en) * 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN106632003B (zh) * 2015-12-31 2019-02-12 上海博志研新药物技术有限公司 一种依托考昔的制备方法
CN108069896B (zh) * 2016-11-11 2022-08-12 昆明积大制药股份有限公司 一种依托考昔晶型的制备方法
CN107417599B (zh) * 2017-06-21 2020-06-09 四川尚锐生物医药有限公司 一种依托考昔晶型的制备方法
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
MX2017009660A (es) 2017-07-26 2017-11-23 Laboratorios Liomont S A De C V Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.
CN107556231A (zh) * 2017-09-23 2018-01-09 江苏正大清江制药有限公司 一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107417600A (zh) * 2017-09-26 2017-12-01 江苏正大清江制药有限公司 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法
CN107898787B (zh) * 2017-12-15 2018-11-30 扬子江药业集团上海海尼药业有限公司 一种药物组合物及其制剂和制备方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN110143915A (zh) * 2019-06-03 2019-08-20 蚌埠学院 一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
CZ292843B6 (cs) * 1996-07-18 2003-12-17 Merck Frosst Canada & Co. Derivát pyridinu a farmaceutický prostředek s jeho obsahem
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP1071745B1 (en) * 1998-04-24 2004-08-04 Merck & Co., Inc. Process for synthesizing cox-2 inhibitors
DK1248618T3 (da) * 1999-11-29 2006-07-10 Merck Frosst Canada Inc Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Also Published As

Publication number Publication date
RS51541B (sr) 2011-06-30
IS2806B (is) 2012-09-15
CA2410234C (en) 2008-05-13
HUP0302336A2 (hu) 2003-11-28
EP1296951A1 (en) 2003-04-02
HRP20020934B1 (en) 2012-01-31
PE20011324A1 (es) 2002-01-28
HK1058932A1 (en) 2004-06-11
CZ20023888A3 (cs) 2003-02-12
PT1296951E (pt) 2010-12-07
JP2004501116A (ja) 2004-01-15
GEP20053492B (en) 2005-04-25
MA26919A1 (fr) 2004-12-20
CA2410234A1 (en) 2001-12-06
JP4142621B2 (ja) 2008-09-03
SI1296951T1 (sl) 2011-01-31
NZ522394A (en) 2004-05-28
NO20025674D0 (no) 2002-11-26
JP3665053B2 (ja) 2005-06-29
IL152582A0 (en) 2003-05-29
HN2001000110A (es) 2002-03-06
EA004809B1 (ru) 2004-08-26
ES2351958T3 (es) 2011-02-14
NO324495B1 (no) 2007-10-29
ATE483687T1 (de) 2010-10-15
ME00428B (me) 2011-10-10
CR6606A (es) 2006-02-06
EE200200655A (et) 2004-08-16
HU228423B1 (en) 2013-03-28
AR028577A1 (es) 2003-05-14
AU2001264804B2 (en) 2006-04-06
TWI303634B (en) 2008-12-01
YU89402A (sh) 2005-11-28
DK1296951T3 (da) 2011-01-24
KR100757699B1 (ko) 2007-09-13
BRPI0111140B1 (pt) 2018-03-13
JO2216B1 (en) 2004-10-07
SV2002000462A (es) 2002-03-08
NO20025674L (no) 2002-11-26
GT200100091A (es) 2001-12-28
WO2001092230A1 (en) 2001-12-06
IN2002CH02089A (enExample) 2005-02-25
UA73355C2 (en) 2005-07-15
HRP20020934A2 (en) 2005-02-28
MY123569A (en) 2006-05-31
EP1296951B1 (en) 2010-10-06
BR0111140A (pt) 2005-01-11
PH12001001175B1 (en) 2006-08-10
AU6480401A (en) 2001-12-11
CN1227233C (zh) 2005-11-16
EE05242B1 (et) 2009-12-15
BG107237A (bg) 2003-05-30
CY1111440T1 (el) 2015-08-05
DE60143197D1 (de) 2010-11-18
JP2005047927A (ja) 2005-02-24
KR20030003762A (ko) 2003-01-10
SK287174B6 (sk) 2010-02-08
IS6630A (is) 2002-11-20
BRPI0111140B8 (pt) 2021-05-25
PL358153A1 (en) 2004-08-09
MXPA02011619A (es) 2003-03-27
MX230696B (es) 2005-09-19
EA200201264A1 (ru) 2003-04-24
IN2007CH05103A (enExample) 2008-08-27
CN1443168A (zh) 2003-09-17
ZA200209558B (en) 2003-10-28
SK16702002A3 (sk) 2003-05-02
PA8516901A1 (es) 2002-04-25
BG65855B1 (bg) 2010-03-31
GC0000362A (en) 2007-03-31

Similar Documents

Publication Publication Date Title
EG24189A (en) 5-chloro-3-(-4-methanesulfonylphenyl)-6-methyl-[2,3] bipyridinyl in pure crystalline form and process for synthesis
PL359600A1 (en) Bar and process thereof
HUP0301802A3 (en) Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
HUP0500983A3 (en) Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
PL361980A1 (en) Method for producing purified hematinic iron-saccharidic complex and product produced
HUP0401081A3 (en) Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
HUP0301651A3 (en) Indolylmaleimide derivatives, pharmaceutical compositions containing them, process for producing them and their use
IL150430A0 (en) Cell division inhibitors and process for producing the same
GB0028179D0 (en) Process for preparing pouches
EP1216621A4 (en) SOFT SWEETS AND METHOD FOR THE PRODUCTION THEREOF
HUP0303118A3 (en) Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
HUP0201785A3 (en) Dihydrobenzodiazepins, process for producing them, their use and pharmaceutical compositions containing them
AU3409001A (en) Novel inulin synthase and process for producing inulin by using the same
GB2366254B (en) Child-vehicle pusher's raincover
EP1207150A4 (en) LONG N-EPSILON CHAIN ACYLLYSIN CRYSTALS, PROCESS FOR PRODUCING THE SAME AND COSMETIC PRODUCTS COMPRISING THESE CRYSTALS
HU0101222D0 (en) Mannite in powder form and process for producing thereof
HUP0002751A3 (en) Novel grignard-reagents and process for producing thereof
AU2001277801A1 (en) Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols
EP1310503A4 (en) PROCESS FOR THE PRODUCTION OF HYDRAZINOMONOSACCHARIDE DERIVATIVES AND THEIR USE
AU2002242348A1 (en) Process for obtaining 3'-epilutein
AU8711801A (en) Methods and compositions for producing a neurosalutary effect in a subject
HUP0201181A3 (en) 1,5-benzodiazepine derivatives, process for producing it and pharmaceutical composition containing it
HUP0300266A3 (en) 1,3,4-oxadiazole derivatives and process for producing the same
IL159514A0 (en) A new process for the synthesis of torsemide, in particular of pure and stable form ii
HUP0300259A3 (en) Process for preparing 5'-acetylstavudine